Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Original Article

P. Sonneveld, M.A. Dimopoulos, M. Boccadoro, H. Quach, P.J. Ho, M. Beksac, C. Hulin, E. Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, F. Gay, R. Mina, I.S. Nijhof, N.W.v.d. Donk, E. Katodritou, F. Schjesvold, A.S. Balari, L. Rosiñol, M. Delforge, W. Roeloffzen, T. Silzle, A. Vangsted, H. Einsele, A. Spencer, R. Hajek, A. Jurczyszyn, S. Lonergan, T. Ahmadi, Y. Liu, J. Wang, D. Vieyra, E.M.v. Brummelen, V. Vanquickelberghe, A. Sitthi-Amorn, C.J.d. Boer, R. Carson, P. Rodriguez-Otero, J. Bladé, and P. Moreau

N Engl J Med 2024;390:301-313

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
01/24/2024
Course expires: 
01/25/2026

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Please sign in or create an account to take the course.